NT-219 Re-sensitizes Cancer to Keytruda, Stopping Tumor Progression, Study Shows
News
Adding TyrNovo‘s NT-219 to Merck’s Keytruda (pembrolizumab) converted Keytruda-resistant tumors into therapy responders, stopping tumor progression, a study reports. The research, which involved a number of cancers, was a collaboration between Bar Ilan University and Rabin ... Read more